A real-world comparative effectiveness analysis of macitentan versus ambrisentan and bosentan on hospitalizations and healthcare resource utilization in patients with pulmonary arterial hypertension
Macitentan was associated with a significantly reduced risk of PAH-related and all-cause hospitalization, with lower ICU healthcare resource utilization, versus other ERAs.
Authors
- Chang Zhi Zhang
- Abbey Thompson
- Carly J. Paoli (ORCID: https://orcid.org/0000-0002-1331-9462)
- Karim El‐Kersh (ORCID: https://orcid.org/0000-0003-1285-3628)
- Sumeet Panjabi (ORCID: https://orcid.org/0000-0002-5093-8510)
- Xiaoqin Tang (ORCID: https://orcid.org/0000-0001-7749-692X)
Institutions
- Johnson & Johnson (United States) (US)
- Banner Health (US)
- Banner - University Medical Center Phoenix (US)
Publication Details
- Journal
- Respiratory Medicine
- Published
- 2025-04-22
- DOI
- https://doi.org/10.1016/j.rmed.2025.108112
- Citations
- 2
- Primary Topic
- Pulmonary Hypertension Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 3.04